10543179

4 known cases. View patent page →

Cases
4
Active
3
1 closed
Filed
2020–2021
Top venue
D. Delaware
2 cases

Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al.

Discovery active through mid-2022; final disposition unverified
Docket:
1:21-cv-00645
Patents:918740510543179
π Novartis Pharmaceuticals Corp.Δ Handa Neuroscience, LLCΔ Handa Pharma, Inc.Δ Handa Pharmaceuticals, Inc.Δ Handa Pharmaceuticals, LLC

Suit against Handa entities asserting the '405 patent and also US 10,543,179. Handa sought summary judgment on the '405 patent after the Federal Circuit's June 2022 invalidation; final disposition not verified.

Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. et al.

active
Docket:
1:20-cv-00133
Filed:
2020-01-28
Patents:105431799187405
π Novartis Pharmaceuticals CorporationΔ HEC Pharm Co., Ltd.Δ HEC Pharm USA, Inc.Δ Sunshine Lake Pharma Co., Ltd.Δ Canda HEC 1 LLCΔ Rising Pharma Holdings, Inc.Δ Glenmark Pharmaceuticals Ltd.

Hatch-Waxman/ANDA patent infringement action by Novartis against HEC and related entities concerning generic fingolimod 0.5 mg capsules. Consolidated with 1:21-cv-01530 and 1:23-cv-00026; claim construction was decided on April 6, 2023 and merits briefing was ongoing.

Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC et al.

dismissed
Docket:
3:21-cv-03397 / 5:21-cv-03397
Filed:
2021-05-06
Patents:105431799187405
π Novartis Pharmaceuticals CorporationΔ Handa Neuroscience, LLCΔ Handa Pharmaceuticals, Inc.Δ Handa Pharma, Inc.Δ Handa Pharmaceuticals, LLC

Protective safety suit filed in the Northern District of California two days after the Delaware Handa suit, asserting the same two patents. Dismissed after the October 2022 Handa settlement.

Untitled case

presumably active
Docket:
1:23-cv-00026
Patents:10543179

Listed on Google Patents as litigation involving US Patent 10,543,179 and consolidated with 1:20-cv-00133. Appears to be part of the HEC consolidated fingolimod ANDA litigation, but parties and filing date were not confirmed.